Impax Asset Management Group plc Takes $5.23 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Impax Asset Management Group plc purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 300,000 shares of the company’s stock, valued at approximately $5,226,000. Impax Asset Management Group plc owned 0.38% of Travere Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. CWM LLC increased its stake in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the period. Creative Planning increased its stake in Travere Therapeutics by 4.3% during the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock worth $335,000 after buying an additional 995 shares during the period. Semanteon Capital Management LP purchased a new stake in Travere Therapeutics during the 3rd quarter worth approximately $513,000. China Universal Asset Management Co. Ltd. increased its stake in Travere Therapeutics by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,712 shares of the company’s stock worth $206,000 after buying an additional 5,767 shares during the period. Finally, Rice Hall James & Associates LLC increased its stake in Travere Therapeutics by 24.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 94,736 shares of the company’s stock worth $1,325,000 after buying an additional 18,562 shares during the period.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 54,244 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at approximately $1,360,250. This trade represents a 49.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Eric M. Dube sold 11,375 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the transaction, the chief executive officer now directly owns 419,173 shares in the company, valued at $10,076,918.92. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 206,335 shares of company stock valued at $4,453,012 in the last ninety days. Insiders own 3.75% of the company’s stock.

Travere Therapeutics Trading Down 3.4 %

NASDAQ TVTX opened at $21.23 on Tuesday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm’s fifty day moving average price is $19.75 and its 200 day moving average price is $16.77. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -5.18 and a beta of 0.72. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The company had revenue of $74.79 million during the quarter, compared to analysts’ expectations of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent research reports. Scotiabank upped their target price on shares of Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 12th. Citigroup upped their target price on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. Piper Sandler upped their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Travere Therapeutics in a research report on Friday. Finally, Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.